Author: jameshebrew

The report features an extensive study of the current landscape and future outlook of the immuno-oncology biomarker testing market (focusing particularly on TMB, MSI and TILs (CD3+, CD4+, CD8+, FOXP3+)).... Read More

Bispecific antibody therapeutics represent a transformative approach to modern treatment; over the years, this upcoming class of ‘two-target’ artificially engineered drugs have generated significant enthusiasm within the medical science community Roots... Read More

In order to avail benefits, such as higher flexibility, reduced cost and assistance in meeting the rising demands, several pharmaceutical companies have demonstrated a preference to outsource their secondary packaging... Read More

Herceptin® sales peaked in 2018, a year before the primary patent covering the drug expired in the US; in order to carve out a share of the associated opportunity, stakeholders... Read More

Over the past few years, protein-based therapeutics, including peptides, hormones, vaccines, monoclonal antibodies, blood factors and therapeutic enzymes, have gained a lot of attention from clinical researchers engaged in the... Read More

The increasing medical diagnostic imaging burden has compelled industry players to develop advanced handheld ultrasound scanners that will enable physicians to accurately visualize all major organ systems for diagnostic purposes... Read More

One of the key objectives of the report was to estimate the existing market size and future growth potential within the top selling biologics market, over the coming decade. Based... Read More

Our estimates suggest that the global AI in energy market is likely to be worth USD 2.1 billion in 2020, and this value is projected to reach USD 30.8 billion... Read More

According to experts, the global vaccines market is anticipated to generate revenues worth USD 100 billion by 2025. Data presented by the WHO indicates that the current global vaccination coverage... Read More

Recombinant glycoprotein therapeutics, which include antibody-based interventions, have emerged as one of the fastest growing classes of pharmacologically active molecules. Till date, over 67% of biologics and 80% of biosimilars... Read More